1. Phylogeny – MAP3K7, commonly known as TAK1, belongs to the large family of mitogen‐activated protein kinase kinase kinases (MAP3Ks). TAK1 is evolutionarily conserved across eukaryotic organisms and has been identified as an ortholog in mammals, including humans, where it plays a central role in transmitting stress and inflammatory signals (fechtner2017transforminggrowthfactor pages 1-1). Within the human kinome, TAK1 is assigned to the MAP3K group as defined in the seminal works by Manning et al. (2002) and is closely related to other kinases that regulate the MAP kinase cascades, as evidenced by its conserved catalytic domain and regulatory features (fechtner2017transforminggrowthfactor pages 1-2, kyriakis2012mammalianmapksignal pages 12-13). Phylogenetic analysis based on sequence homology supports the notion that TAK1’s kinase domain and its requirement for binding accessory proteins (TAB1, TAB2, and TAB3) are conserved from lower eukaryotes to humans, placing it in a distinct evolutionary branch of serine/threonine kinases (goff2016heterozygousmutationsin pages 1-2, kyriakis2012mammalianmapksignal pages 13-14).
2. Reaction Catalyzed – TAK1 is a serine/threonine protein kinase that catalyzes the transfer of a phosphate group from adenosine triphosphate (ATP) to specific serine or threonine residues on substrate proteins. The reaction can be summarized as follows:  
   ATP + [protein]−(L-serine or L-threonine) → ADP + [protein]−(L-serine/threonine)-phosphate + H⁺ (fechtner2017transforminggrowthfactor pages 1-1).
3. Cofactor Requirements – Like most kinases operating in intracellular signaling pathways, the catalytic activity of TAK1 is dependent on divalent cations. In particular, magnesium ions (Mg²⁺) are required as essential cofactors for ATP binding, facilitating the phosphoryl transfer reaction that is central to TAK1’s enzymatic function (fechtner2017transforminggrowthfactor pages 1-1).
4. Substrate Specificity – The substrate specificity of TAK1, as a member of the MAP3K family, is determined largely by its kinase domain configuration and the surrounding amino acid environment of the phosphorylation site. According to the comprehensive atlas of serine/threonine kinase substrate specificities, MAP3K family members, including TAK1, show a preference for phosphorylating threonine residues with specific sequence characteristics, such as a predominantly favored glutamine residue at the +1 position relative to the phospho-acceptor (johnson2023anatlasof pages 2-3, johnson2023anatlasof pages 4-5). This motif-based preference is thought to direct TAK1 activity toward substrates involved in stress signaling and inflammatory responses, although the precise consensus sequence may be refined further by integrating additional phosphoproteomic datasets.
5. Structure – TAK1 displays a canonical serine/threonine kinase domain that is centrally positioned within the protein. In human TAK1, the catalytic domain is approximately delineated between amino acids 30 and 306, as described in mutation mapping studies, and is typically flanked by regulatory segments that mediate protein–protein interactions (goff2016heterozygousmutationsin pages 1-2). The protein structure consists of a bilobal architecture with an N-terminal lobe largely comprised of β-sheets and a C-terminal lobe formed predominantly of α-helices. The hinge region connecting these lobes forms the ATP-binding cleft, which is essential for catalytic activity. Key catalytic features include a conserved lysine residue responsible for phosphate transfer (often denoted Lys63 in TAK1), a characteristic DFG motif that participates in positioning divalent cations, and an activation loop containing critical phosphorylation sites such as Thr184, Thr187, and Ser192 (fechtner2017transforminggrowthfactor pages 5-6, fechtner2017transforminggrowthfactor pages 7-8, kyriakis2012mammalianmapksignal pages 13-14). This activation loop undergoes autophosphorylation, a process that is essential for full kinase activation. In addition, the C-terminal portion of TAK1 may form coiled-coil domains, which are implicated in mediating interactions with TAK1-binding proteins (TAB1, TAB2, and TAB3) that are integral to its regulatory mechanism (goff2016heterozygousmutationsin pages 1-2).
6. Regulation – TAK1’s activity is modulated by multiple layers of regulation that ensure precise control of downstream signaling events. A primary regulatory mechanism is autophosphorylation within its activation loop – specifically at residues Thr184, Thr187, and Ser192 – which is critical for achieving a catalytically active conformation (fechtner2017transforminggrowthfactor pages 5-6, fechtner2017transforminggrowthfactor pages 7-8). In addition to autophosphorylation, TAK1 is subject to ubiquitination events; K63-linked polyubiquitination of adaptor proteins such as TRAF6 facilitates the recruitment and assembly of a TAK1 complex via interactions with TAB proteins (TAB1, TAB2, and TAB3), which is necessary for its full activation (fechtner2017transforminggrowthfactor pages 1-2, fechtner2017transforminggrowthfactor pages 6-7, goff2016heterozygousmutationsin pages 4-6). Protein phosphatases, exemplified by protein phosphatase 6, can dephosphorylate TAK1, thereby attenuating its activity and providing a mechanism for signal termination (fechtner2017transforminggrowthfactor pages 5-6). These regulated phosphorylation and ubiquitination events enable TAK1 to integrate upstream signals from receptors such as those for IL-1, TNF-α, and TGF-β, and consequently modulate downstream activation of NF-κB and MAPK cascades (kyriakis2012mammalianmapksignal pages 13-14).
7. Function – TAK1 functions as an essential signaling hub in cells, mediating responses initiated by a variety of extracellular stimuli. It is activated downstream of receptors for pro-inflammatory cytokines – including interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α) – as well as toll-like receptors (TLRs) and transforming growth factor-beta (TGF-β) receptors (fechtner2017transforminggrowthfactor pages 1-1, fechtner2017transforminggrowthfactor pages 1-2). Once activated, TAK1 phosphorylates and activates several MAP kinase kinases (MKKs), thereby initiating cascades that lead to the activation of the JNK, p38 MAPK, and NF-κB pathways (fechtner2017transforminggrowthfactor pages 3-4, kyriakis2012mammalianmapksignal pages 13-14). This positioning makes TAK1 critical for the control of inflammatory gene expression, cellular stress responses, apoptosis, and immune regulation. Moreover, mutations in MAP3K7 have been implicated in developmental disorders such as cardiospondylocarpofacial syndrome (CSCF), underscoring the importance of TAK1 in both immune homeostasis and developmental processes (goff2016heterozygousmutationsin pages 7-7).
8. Other Comments – Several inhibitors targeting TAK1 have been developed and investigated as potential therapeutic agents, particularly in the context of inflammatory and oncologic diseases. Notable among these is the fungal metabolite 5Z-7-oxozeaenol, which acts as an irreversible TAK1 inhibitor, and LYTAK1, which is noted for its oral bioavailability and selectivity (fechtner2017transforminggrowthfactor pages 5-5, fechtner2017transforminggrowthfactor pages 5-6). In addition, heterozygous mutations in MAP3K7 have been linked to cardiospondylocarpofacial syndrome, highlighting the clinical relevance of TAK1 not only in inflammatory signaling but also in developmental regulation (goff2016heterozygousmutationsin pages 1-2, goff2016heterozygousmutationsin pages 7-7). Because TAK1 is a central mediator in the activation of NF-κB and MAPK pathways, aberrant TAK1 signaling has been associated with chronic inflammatory conditions such as rheumatoid arthritis, osteoarthritis, and gout, as well as with certain cancers (fechtner2017transforminggrowthfactor pages 1-1, fechtner2017transforminggrowthfactor pages 7-8, kyriakis2012mammalianmapksignal pages 13-14). These observations have spurred significant interest in the design of selective kinase inhibitors to modulate TAK1 activity in disease states.
9. References
10. fechtner2017transforminggrowthfactor pages 1-1, fechtner2017transforminggrowthfactor pages 1-2, fechtner2017transforminggrowthfactor pages 3-4, fechtner2017transforminggrowthfactor pages 4-5, fechtner2017transforminggrowthfactor pages 6-7, fechtner2017transforminggrowthfactor pages 7-8
11. goff2016heterozygousmutationsin pages 1-2, goff2016heterozygousmutationsin pages 4-6, goff2016heterozygousmutationsin pages 7-7
12. johnson2023anatlasof pages 2-3, johnson2023anatlasof pages 4-5
13. kyriakis2012mammalianmapksignal pages 12-13, kyriakis2012mammalianmapksignal pages 13-14

References

1. (fechtner2017transforminggrowthfactor pages 1-1): Sabrina Fechtner, David A. Fox, and Salahuddin Ahmed. Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology, pages kew301, Aug 2017. URL: https://doi.org/10.1093/rheumatology/kew301, doi:10.1093/rheumatology/kew301. This article has 49 citations and is from a peer-reviewed journal.
2. (fechtner2017transforminggrowthfactor pages 1-2): Sabrina Fechtner, David A. Fox, and Salahuddin Ahmed. Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology, pages kew301, Aug 2017. URL: https://doi.org/10.1093/rheumatology/kew301, doi:10.1093/rheumatology/kew301. This article has 49 citations and is from a peer-reviewed journal.
3. (fechtner2017transforminggrowthfactor pages 3-4): Sabrina Fechtner, David A. Fox, and Salahuddin Ahmed. Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology, pages kew301, Aug 2017. URL: https://doi.org/10.1093/rheumatology/kew301, doi:10.1093/rheumatology/kew301. This article has 49 citations and is from a peer-reviewed journal.
4. (fechtner2017transforminggrowthfactor pages 5-5): Sabrina Fechtner, David A. Fox, and Salahuddin Ahmed. Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology, pages kew301, Aug 2017. URL: https://doi.org/10.1093/rheumatology/kew301, doi:10.1093/rheumatology/kew301. This article has 49 citations and is from a peer-reviewed journal.
5. (fechtner2017transforminggrowthfactor pages 5-6): Sabrina Fechtner, David A. Fox, and Salahuddin Ahmed. Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology, pages kew301, Aug 2017. URL: https://doi.org/10.1093/rheumatology/kew301, doi:10.1093/rheumatology/kew301. This article has 49 citations and is from a peer-reviewed journal.
6. (fechtner2017transforminggrowthfactor pages 7-8): Sabrina Fechtner, David A. Fox, and Salahuddin Ahmed. Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology, pages kew301, Aug 2017. URL: https://doi.org/10.1093/rheumatology/kew301, doi:10.1093/rheumatology/kew301. This article has 49 citations and is from a peer-reviewed journal.
7. (johnson2023anatlasof pages 2-3): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 436 citations and is from a highest quality peer-reviewed journal.
8. (johnson2023anatlasof pages 4-5): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 436 citations and is from a highest quality peer-reviewed journal.
9. (fechtner2017transforminggrowthfactor pages 4-5): Sabrina Fechtner, David A. Fox, and Salahuddin Ahmed. Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology, pages kew301, Aug 2017. URL: https://doi.org/10.1093/rheumatology/kew301, doi:10.1093/rheumatology/kew301. This article has 49 citations and is from a peer-reviewed journal.
10. (fechtner2017transforminggrowthfactor pages 6-7): Sabrina Fechtner, David A. Fox, and Salahuddin Ahmed. Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology, pages kew301, Aug 2017. URL: https://doi.org/10.1093/rheumatology/kew301, doi:10.1093/rheumatology/kew301. This article has 49 citations and is from a peer-reviewed journal.
11. (goff2016heterozygousmutationsin pages 1-2): Carine Le Goff, Curtis Rogers, Wilfried Le Goff, Graziella Pinto, Damien Bonnet, Maya Chrabieh, Olivier Alibeu, Patrick Nistchke, Arnold Munnich, Capucine Picard, and Valérie Cormier-Daire. Heterozygous mutations in map3k7, encoding tgf-β-activated kinase 1, cause cardiospondylocarpofacial syndrome. American journal of human genetics, 99 2:407-13, Aug 2016. URL: https://doi.org/10.1016/j.ajhg.2016.06.005, doi:10.1016/j.ajhg.2016.06.005. This article has 48 citations and is from a highest quality peer-reviewed journal.
12. (goff2016heterozygousmutationsin pages 4-6): Carine Le Goff, Curtis Rogers, Wilfried Le Goff, Graziella Pinto, Damien Bonnet, Maya Chrabieh, Olivier Alibeu, Patrick Nistchke, Arnold Munnich, Capucine Picard, and Valérie Cormier-Daire. Heterozygous mutations in map3k7, encoding tgf-β-activated kinase 1, cause cardiospondylocarpofacial syndrome. American journal of human genetics, 99 2:407-13, Aug 2016. URL: https://doi.org/10.1016/j.ajhg.2016.06.005, doi:10.1016/j.ajhg.2016.06.005. This article has 48 citations and is from a highest quality peer-reviewed journal.
13. (goff2016heterozygousmutationsin pages 7-7): Carine Le Goff, Curtis Rogers, Wilfried Le Goff, Graziella Pinto, Damien Bonnet, Maya Chrabieh, Olivier Alibeu, Patrick Nistchke, Arnold Munnich, Capucine Picard, and Valérie Cormier-Daire. Heterozygous mutations in map3k7, encoding tgf-β-activated kinase 1, cause cardiospondylocarpofacial syndrome. American journal of human genetics, 99 2:407-13, Aug 2016. URL: https://doi.org/10.1016/j.ajhg.2016.06.005, doi:10.1016/j.ajhg.2016.06.005. This article has 48 citations and is from a highest quality peer-reviewed journal.
14. (kyriakis2012mammalianmapksignal pages 12-13): John M. Kyriakis and Joseph Avruch. Mammalian mapk signal transduction pathways activated by stress and inflammation: a 10-year update. Physiological Reviews, 92:689-737, Apr 2012. URL: https://doi.org/10.1152/physrev.00028.2011, doi:10.1152/physrev.00028.2011. This article has 1604 citations and is from a highest quality peer-reviewed journal.
15. (kyriakis2012mammalianmapksignal pages 13-14): John M. Kyriakis and Joseph Avruch. Mammalian mapk signal transduction pathways activated by stress and inflammation: a 10-year update. Physiological Reviews, 92:689-737, Apr 2012. URL: https://doi.org/10.1152/physrev.00028.2011, doi:10.1152/physrev.00028.2011. This article has 1604 citations and is from a highest quality peer-reviewed journal.